Current research on the clinical outcome of phenylketonuria (PKU) patients has mainly explored the possible consequences of late exposure to high phenylalanine (Phe) levels in early-treated adult and elderly patients. However, despite the progressively earlier diagnosis and treatment of PKU, the neonatal and infancy periods remain the most vulnerable periods of the brain to Phe, which may cause permanent impairment of early- and late-emerging cognitive functions. The few studies that have measured Phe exposure during the first month of life, before metabolic control is achieved, confirm Phe exposure during the first month as a factor contributing to the final outcome of the disease.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Blau, N., van Spronsen, F. J. & Levy, H. L. Phenylketonuria. Lancet 376, 1417–1427 (2010).
Smith, I., Beasley, M. G. & Ades, A. E. Intelligence and quality of dietary treatment in phenylketonuria. Arch. Dis. Child. 65, 472–478 (1990).
Waisbren, S. E. et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 92, 63–70 (2007).
Hofman, D. L., Champ, C. L., Lawton, C. L., Henderson, M. & Dye, L. A systematic review of cognitive functioning in early treated adults with phenylketonuria. Orphanet J. Rare Dis. 13, 150 (2018).
Leuzzi, V., Chiarotti, F., Nardecchia, F., van Vliet, D. & van Spronsen, F. J. Predictability and inconsistencies of cognitive outcome in patients with phenylketonuria and personalised therapy: the challenge for the future guidelines. J. Med. Genet. 57, 145–150 (2020).
Beasley, M. G., Costello, P. M. & Smith, I. Outcome of treatment in young adults with phenylketonuria detected by routine neonatal screening between 1964 and 1971. Q. J. Med. 87, 155–160 (1994).
DeRoche, K. & Welsh, M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev. Neuropsychol. 33, 474–504 (2008).
Palermo, L. et al. Cognitive outcomes in early-treated adults with phenylketonuria (PKU): a comprehensive picture across domains. Neuropsychology 31, 255–267 (2017).
Romani, C. et al. The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: effects across tasks and developmental stages. Neuropsychology 31, 242–254 (2017).
Aitkenhead, L. et al. Long‐term cognitive and psychosocial outcomes in adults with phenylketonuria. J. Inherit. Metab. Dis. https://doi.org/10.1002/jimd.12413 (2021).
Vockley, J. et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet. Med. 16, 188–200 (2014).
van Spronsen, F. J. et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 5, 743–756 (2017).
van Wegberg, A. M. J. et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J. Rare Dis. 12, 162 (2017).
Cardona, F., Leuzzi, V., Antonozzi, I., Benedetti, P. & Loizzo, A. The development of auditory and visual evoked potentials in early treated phenylketonuric children. Electroencephalogr. Clin. Neurophysiol. 80, 8–15 (1991).
Diamond, A., Prevor, M. B., Callender, G. & Druin, D. P. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr. Soc. Res. Child Dev. 62, 1–208 (1997).
Cleary, M. et al. Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes. Mol. Genet. Metab. 110, 418–423 (2013).
Liemburg, G. B. et al. Metabolic control during the neonatal period in phenylketonuria: associations with childhood IQ. Pediatr. Res. https://doi.org/10.1038/s41390-021-01728-8 (2021).
Jahja, R., Huijbregts, S. C. J., de Sonneville, L. M. J., van der Meere, J. J. & van Spronsen, F. J. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J. Pediatrics 164, 895.e2–899.e2 (2014).
de la Parra, A., García, M. I., Waisbren, S. E., Cornejo, V. & Raimann, E. Cognitive functioning in mild hyperphenylalaninemia. Mol. Genet. Metab. Rep. 5, 72–75 (2015).
de la Parra, A. et al. First-year metabolic control guidelines and their impact on future metabolic control and neurocognitive functioning in children with PKU. Mol. Genet. Metab. Rep. 13, 90–94 (2017).
Weglage, J. et al. Neurocognitive functioning in adults with phenylketonuria: results of a long term study. Mol. Genet. Metab. 110, S44–S48 (2013).
Pilotto, A. et al. Phenylalanine effects on brain function in adult phenylketonuria. Neurology 96, e399–e411 (2021).
Acknowledgements
We would like to thank Dr. Flavia Chiarotti for her punctual and always valuable conversations on methodological issues.
Author information
Authors and Affiliations
Contributions
V.L. and F.N. made substantial contributions to the conception and design of the paper; drafting the article and revising it critically for important intellectual content; they approved the final version to be published.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Leuzzi, V., Nardecchia, F. Looking back at the neonatal period in early-treated phenylketonuric patients. Pediatr Res 91, 730–732 (2022). https://doi.org/10.1038/s41390-022-01937-9
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41390-022-01937-9
